Diagnosis And Treatment Of 32 Cases Of Pulmonary Sclerosing Pneumocytoma

Objective: Pulmonary sclerosing pneumocytoma(PSP)is a clinicall y rare,benign tumor of slow growth,because of its low incidence,the clinical data of existing less,clinical diagnosis,treatment and differential diagnosis of PSP still exist certain difficulties.In this stud y,the diagnosis,trea tment,imaging,pathological manifestations and other clinical features of the disease were discussed to increase the understanding of the disease and improve the level of diagnosis and treatment of the disease.Methods: Clinical data of 32 patients with PSP confirmed b y postoperative pathology in the Department of Thoracic Surgery,Shengjing Hospital,China Medical University from January 2011 to December 2019 were retrospectivel y anal yzed.Results: There were 32 patien ts in this study,including 3 males and 29 females,with an average age of 49.63 years old.Fifteen patients had clinical s ymptoms,such as cough,d ys pnea,chest pain,etc.Seventeen patients were treated because of mass shadow found in routine ph ysical examination.Most imaging examinations showed an isolated circular mass shadow,lacking specificit y.Preoperative imaging diagnosis was prone to misdiagnosis,and most patients could onl y be diagnosed b y postoperative pathology.Laboratory tests found slight increase in NSE in 4 cases,increase in ESR in 1 case,increase in CYFRA21-1 cytokeratin 19 fragment in 3 cases,and no positive findings were found in other laboratory tests.SUVmax of preoperative PET-CT examination for the two patients in this group was greater than 2.5,suggesting that the diagnostic rate of PET-CT may be low.All patients underwent surgical treatment and recovered well after surgery.There was no recurrence or metastasis in the follow-up of 28 cases.Conclusion: Sclerosing pulmonary c ell tumor(PSP)is more likel y to occur in middle-aged women,and there is no significant relationship between the incidence and smoking history.There is no significant difference in the age of onset between men and women(P > 0.05).The clinical manifesta tions of PSP may be related to tumor size and growth location,and the s ymptoms are not specific.PSP grew slowl y,surgery was the preferred treatment,and the overall prognosis was good.PET-CT may have a low diagnostic rate.Laboratory studies suggest th at elevated NSE and CYFRA21-1 cytokeratin 19 fragments may be associated with PSP.